TERN
Terns Pharmaceuticals, Inc.
Price Chart
Latest Quote
$52.95
-0.02 (-0.03%)
Current Price
| Previous Close | $52.97 |
| Open | $52.97 |
| Day High | $52.97 |
| Day Low | $52.97 |
| Volume | 6,331,482 |
Stock Information
| Shares Outstanding | 115.52M |
| Total Debt | $919K |
| Cash Equivalents | $1.02B |
| Net Income | $-96.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.12B |
| EPS (TTM) | $-1.03 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.09B |
| Income | $-96.21M |
| Book/sh | $8.96 |
| Cash/sh | $8.82 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 62.09 |
| Current Ratio | 62.41 |
| Debt/Eq | 0.09 |
Returns & Margins
| ROA | -9.91% |
| ROE | -14.23% |
Ownership
| Insider Ownership | 0.25% |
| Institutional Ownership | 109.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -34.01 |
| P/B | 5.91 |
Analyst Data
| Recommendation | hold |
| Target Price | $53.00 |
Technical Indicators
| SMA20 | $52.83 |
| SMA50 | $49.92 |
| SMA200 | $28.46 |
| RSI | 85.71 |
| ATR | 0.0543 |
| Shares Float | 115.12M |
| Short Float | 6.99% |
| Short Ratio | 0.70 |
| Volatility | -0.38 |
Performance History
| Week | +0.04% |
| Month | +0.55% |
| Quarter | +49.83% |
| 6 Months | +203.79% |
| YTD | +32.01% |
| Year | +1659.14% |
| 3 Years | +337.60% |
| 5 Years | +140.68% |
| 10 Years | +187.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-05-07 | $52.95 | 0 |
| 2026-05-06 | $52.95 | 0 |
| 2026-05-05 | $52.95 | 0 |
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
đ° Latest News
Is Merck & Co. Stock Outperforming the S&P 500?
Barchart âĸ 2026-05-29T10:50:30Z
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
Motley Fool âĸ 2026-05-16T15:01:01Z
MSD concludes Terns acquisition to expand CML pipeline
Hospital Management âĸ 2026-05-06T09:47:44Z
Merck still sees âcompellingâ outlook for Terns leukemia drug
BioPharma Dive âĸ 2026-04-30T12:21:00Z
Merck Advances Terns Deal And Cardiovascular And RSV Growth Options
Simply Wall St. âĸ 2026-04-26T23:06:07Z
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
Insider Monkey âĸ 2026-04-17T17:54:43Z
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
Zacks âĸ 2026-04-09T13:18:00Z
Why Terns Pharmaceuticals Stock Rocked the Market in March
Motley Fool âĸ 2026-04-08T18:20:57Z
Merckâs Terns Deal Targets Cancer Pipeline And Keytruda Patent Risks
Simply Wall St. âĸ 2026-04-07T15:16:21Z
Terns rebuffed a higher bid before selling to Merck
BioPharma Dive âĸ 2026-04-07T12:28:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $110,124,000 | $101,871,000 | $102,558,000 | $62,029,000 |
| Other Income Expense | $-93,000 | $-11,000 | $-314,000 | $-68,000 |
| Other Non Operating Income Expenses | $-93,000 | $-11,000 | $-314,000 | $-68,000 |
| Net Non Operating Interest Income Expense | $14,591,000 | $13,289,000 | $12,901,000 | $2,110,000 |
| Operating Expense | $110,124,000 | $101,871,000 | $102,558,000 | $62,029,000 |
| General And Administrative Expense | $32,235,000 | $31,759,000 | $39,061,000 | $22,412,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Net Interest Income | $14,591,000 | $13,289,000 | $12,901,000 | $2,110,000 |
| Interest Income | $14,591,000 | $13,289,000 | $12,901,000 | $2,110,000 |
| Normalized Income | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Net Income From Continuing And Discontinued Operation | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Total Operating Income As Reported | $-110,124,000 | $-101,871,000 | $-102,558,000 | $-62,029,000 |
| Net Income Common Stockholders | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Net Income | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Net Income Including Noncontrolling Interests | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Net Income Continuous Operations | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Pretax Income | $-95,626,000 | $-88,593,000 | $-89,971,000 | $-59,987,000 |
| Interest Income Non Operating | $14,591,000 | $13,289,000 | $12,901,000 | $2,110,000 |
| Operating Income | $-110,124,000 | $-101,871,000 | $-102,558,000 | $-62,029,000 |
| Per Share | ||||
| Diluted EPS | - | $-1.12 | $-1.27 | $-1.67 |
| Basic EPS | - | $-1.12 | $-1.27 | $-1.67 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-109,623,000 | $-100,975,000 | $-101,677,000 | $-60,997,000 |
| Reconciled Depreciation | $501,000 | $896,000 | $881,000 | $1,032,000 |
| EBITDA (Bullshit earnings) | $-109,623,000 | $-100,975,000 | $-101,677,000 | $-60,997,000 |
| EBIT | $-110,124,000 | $-101,871,000 | $-102,558,000 | $-62,029,000 |
| Diluted NI Availto Com Stockholders | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Tax Provision | $581,000 | $260,000 | $239,000 | $358,000 |
| Research And Development | $77,889,000 | $70,112,000 | $63,497,000 | $39,617,000 |
| Selling General And Administration | $32,235,000 | $31,759,000 | $39,061,000 | $22,412,000 |
| Other Gand A | $32,235,000 | $31,759,000 | $39,061,000 | $22,412,000 |
| Diluted Average Shares | - | $79,507,474 | $71,259,239 | $36,033,045 |
| Basic Average Shares | - | $79,507,474 | $71,259,239 | $36,033,045 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
| Minority Interests | - | - | - | - |
Fetched: 2026-05-05
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Total Assets | $1,025,078,000 | $363,929,000 | $268,517,000 | $287,026,000 |
| Total Non Current Assets | $884,000 | $1,820,000 | $1,085,000 | $1,841,000 |
| Current Assets | $1,024,194,000 | $362,109,000 | $267,432,000 | $285,185,000 |
| Other Current Assets | $5,212,000 | $3,945,000 | $3,992,000 | $2,071,000 |
| Cash Cash Equivalents And Short Term Investments | $1,018,982,000 | $358,164,000 | $263,440,000 | $283,114,000 |
| Cash And Cash Equivalents | $524,747,000 | $161,439,000 | $79,926,000 | $143,235,000 |
| Cash Equivalents | $500,789,000 | $147,566,000 | $33,788,000 | $23,029,000 |
| Cash Financial | $23,958,000 | $13,873,000 | $46,138,000 | $120,206,000 |
| Other Non Current Assets | - | $350,000 | $56,000 | $37,000 |
| Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Receivables | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $919,000 | $1,347,000 | $603,000 | $1,205,000 |
| Long Term Debt And Capital Lease Obligation | $445,000 | $919,000 | $0 | $544,000 |
| Current Debt And Capital Lease Obligation | $474,000 | $428,000 | $603,000 | $661,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $18,554,000 | $18,059,000 | $13,150,000 | $10,083,000 |
| Total Non Current Liabilities Net Minority Interest | $2,143,000 | $2,409,000 | $1,206,000 | $1,615,000 |
| Tradeand Other Payables Non Current | $1,698,000 | $1,490,000 | $1,206,000 | $1,071,000 |
| Current Liabilities | $16,411,000 | $15,650,000 | $11,944,000 | $8,468,000 |
| Other Current Liabilities | $449,000 | $455,000 | $278,000 | $185,000 |
| Payables And Accrued Expenses | $8,571,000 | $6,855,000 | $5,380,000 | $3,779,000 |
| Payables | $1,721,000 | $2,148,000 | $2,515,000 | $1,645,000 |
| Accounts Payable | $1,721,000 | $2,148,000 | $2,515,000 | $1,645,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Total Equity Gross Minority Interest | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Stockholders Equity | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Gains Losses Not Affecting Retained Earnings | $260,000 | $-279,000 | $-19,000 | $-822,000 |
| Other Equity Adjustments | $260,000 | $-279,000 | $-19,000 | $-822,000 |
| Retained Earnings | $-517,688,000 | $-421,481,000 | $-332,628,000 | $-242,418,000 |
| Other | ||||
| Ordinary Shares Number | $112,324,683 | $87,126,583 | $64,576,719 | $53,723,171 |
| Share Issued | $112,324,683 | $87,126,583 | $64,576,719 | $53,723,171 |
| Tangible Book Value | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Invested Capital | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Working Capital | $1,007,783,000 | $346,459,000 | $255,488,000 | $276,717,000 |
| Capital Lease Obligations | $919,000 | $1,347,000 | $603,000 | $1,205,000 |
| Total Capitalization | $1,006,524,000 | $345,870,000 | $255,367,000 | $276,943,000 |
| Additional Paid In Capital | $1,523,941,000 | $767,621,000 | $588,008,000 | $520,178,000 |
| Capital Stock | $11,000 | $9,000 | $6,000 | $5,000 |
| Common Stock | $11,000 | $9,000 | $6,000 | $5,000 |
| Long Term Capital Lease Obligation | $445,000 | $919,000 | $0 | $544,000 |
| Current Capital Lease Obligation | $474,000 | $428,000 | $603,000 | $661,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,917,000 | $7,912,000 | $5,683,000 | $3,843,000 |
| Current Accrued Expenses | $6,850,000 | $4,707,000 | $2,865,000 | $2,134,000 |
| Net PPE | $884,000 | $1,470,000 | $1,029,000 | $1,804,000 |
| Accumulated Depreciation | $-682,000 | $-1,892,000 | $-1,609,000 | $-1,402,000 |
| Gross PPE | $1,566,000 | $3,362,000 | $2,638,000 | $3,206,000 |
| Leases | $181,000 | $750,000 | $734,000 | $758,000 |
| Machinery Furniture Equipment | $548,000 | $617,000 | $611,000 | $643,000 |
| Buildings And Improvements | $837,000 | $1,248,000 | $523,000 | $1,047,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $494,235,000 | $196,725,000 | $183,514,000 | $139,879,000 |
| Other Properties | - | $747,000 | $770,000 | $758,000 |
| Preferred Stock | - | - | - | - |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-05-05
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,176,000 | $-70,058,000 | $-67,442,000 | $-49,384,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,176,000 | $-70,016,000 | $-67,390,000 | $-49,109,000 |
| Cash Flow From Continuing Operating Activities | $-82,176,000 | $-70,016,000 | $-67,390,000 | $-49,109,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-298,043,000 | $-12,410,000 | $-37,987,000 | $-22,272,000 |
| Cash Flow From Continuing Investing Activities | $-298,043,000 | $-12,410,000 | $-37,987,000 | $-22,272,000 |
| Capital Expenditure | - | $-42,000 | $-52,000 | $-275,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $706,388,000 | $162,312,000 | $41,611,000 | $167,253,000 |
| Financing Cash Flow | $743,511,000 | $163,995,000 | $41,951,000 | $167,095,000 |
| Cash Flow From Continuing Financing Activities | $743,511,000 | $163,995,000 | $41,951,000 | $167,095,000 |
| Net Other Financing Charges | $-235,000 | $-388,000 | $-344,000 | $-401,000 |
| Net Common Stock Issuance | $706,388,000 | $162,312,000 | $41,611,000 | $167,253,000 |
| Common Stock Issuance | $706,388,000 | $162,312,000 | $41,611,000 | $167,253,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $218,000 | $60,000 | $28,000 | $3,000 |
| End Cash Position | $524,747,000 | $161,439,000 | $79,926,000 | $143,235,000 |
| Beginning Cash Position | $161,439,000 | $79,926,000 | $143,235,000 | $47,699,000 |
| Effect Of Exchange Rate Changes | $16,000 | $-56,000 | $117,000 | $-178,000 |
| Changes In Cash | $363,292,000 | $81,569,000 | $-63,426,000 | $95,714,000 |
| Proceeds From Stock Option Exercised | $37,358,000 | $2,071,000 | $684,000 | $243,000 |
| Net Investment Purchase And Sale | $-298,043,000 | $-12,368,000 | $-37,935,000 | $-21,997,000 |
| Sale Of Investment | $107,000,000 | $157,574,000 | $237,846,000 | $117,734,000 |
| Purchase Of Investment | $-405,043,000 | $-169,942,000 | $-275,781,000 | $-139,731,000 |
| Net PPE Purchase And Sale | $0 | $-42,000 | $-52,000 | $-275,000 |
| Purchase Of PPE | $0 | $-42,000 | $-52,000 | $-275,000 |
| Change In Working Capital | $-321,000 | $4,381,000 | $1,475,000 | $-1,037,000 |
| Change In Other Current Liabilities | $-430,000 | $-555,000 | $-666,000 | $-610,000 |
| Change In Payables And Accrued Expense | $1,290,000 | $4,889,000 | $4,062,000 | $694,000 |
| Change In Accrued Expense | $1,802,000 | $5,256,000 | $2,913,000 | $1,416,000 |
| Change In Interest Payable | $1,173,000 | $1,012,000 | $184,000 | - |
| Change In Payable | $-512,000 | $-367,000 | $1,149,000 | $-722,000 |
| Change In Account Payable | $-512,000 | $-367,000 | $1,149,000 | $-722,000 |
| Change In Prepaid Assets | $-1,181,000 | $47,000 | $-1,921,000 | $-1,121,000 |
| Stock Based Compensation | $13,398,000 | $15,627,000 | $25,536,000 | $10,768,000 |
| Amortization Of Securities | $-58,000 | $-2,090,000 | $-5,213,000 | $81,000 |
| Deferred Tax | $511,000 | $23,000 | $141,000 | $392,000 |
| Deferred Income Tax | $511,000 | $23,000 | $141,000 | $392,000 |
| Depreciation Amortization Depletion | $501,000 | $896,000 | $881,000 | $1,032,000 |
| Depreciation And Amortization | $501,000 | $896,000 | $881,000 | $1,032,000 |
| Depreciation | $501,000 | $896,000 | $881,000 | $1,032,000 |
| Net Income From Continuing Operations | $-96,207,000 | $-88,853,000 | $-90,210,000 | $-60,345,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | $-610,000 |
| Change In Other Current Assets | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-05-05